Skip to main content
Scholar Rock Holding Corp logo

Scholar Rock Holding Corp — Investor Relations & Filings

Ticker · SRRK ISIN · US80706P1030 LEI · 549300Z1FLPGL4OWJ459 US Professional, scientific and technical activities
Open in API
Filings indexed 605 across all filing types
Latest filing 2020-08-07 Regulatory Filings
Country US United States of America
Listing US SRRK

About Scholar Rock Holding Corp

https://scholarrock.com/

Scholar Rock Holding Corp. is a late-stage biopharmaceutical company that discovers, develops, and delivers therapies for serious diseases, with a focus on neuromuscular disorders. The company's scientific approach is centered on selectively targeting protein growth factors in their latent, inactive state. This proprietary platform aims to modulate biological functions with high specificity, representing a novel method compared to traditional approaches that target already activated proteins. Founded on pioneering research from Harvard Medical School and Boston Children's Hospital, Scholar Rock is developing a new class of medicines to address the underlying causes of disease.

Recent filings

Filing Released Lang Actions
SCHOLAR ROCK HOLDING CORPORATION 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 6, 2020, reporting the issuance of a press release announcing financial and operating results for the quarter ended June 30, 2020. It also mentions a live conference call and webcast to discuss the second quarter 2020 financial results and business progress, along with a slide deck presentation. The document itself does not contain the financial results or detailed analysis but rather announces the release of these materials and the event. The document length is 4174 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement of a report and related materials, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain the full financial report or transcript.
2020-08-07 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-07 English
FORM 4 -
Director's Dealing
2020-07-17 English
FORM 4 -
Director's Dealing
2020-07-17 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the resignation of the CEO and CFO, appointment of new CEO and CFO, their employment agreements, compensation details, and related board changes. There are no financial statements or comprehensive financial performance data included. The primary subject is changes in the company's board of directors and senior management, which aligns with the category for Board/Management Information (MANG). The document is detailed and lengthy (15,000 characters), so it is not a brief announcement or a report publication notice. Therefore, the correct classification is MANG with high confidence.
2020-07-16 English
FORM 3 -
Director's Dealing
2020-06-18 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.